Welcome to our dedicated page for Neurocrine Biosciences news (Ticker: NBIX), a resource for investors and traders seeking the latest updates and insights on Neurocrine Biosciences stock.
Neurocrine Biosciences Inc (Nasdaq: NBIX) is a neuroscience-focused biopharmaceutical company whose news flow centers on clinical data, product performance and pipeline progress in movement disorders, neuropsychiatry, endocrinology and metabolic disease. The company regularly issues updates on its flagship VMAT2 inhibitor INGREZZA (valbenazine) for tardive dyskinesia and chorea associated with Huntington’s disease, including head-to-head pharmacologic studies, long-term efficacy analyses and peer-reviewed publications.
NBIX news commonly features clinical trial readouts across its pipeline. Recent releases have covered Phase 3 and Phase 4 data for INGREZZA in tardive dyskinesia and Huntington’s disease chorea, a Phase 3 study of valbenazine in dyskinetic cerebral palsy, and Phase 2 results for investigational compounds such as NBI-1070770 in major depressive disorder. Investors and clinicians can also follow updates on late-stage programs including osavampator for major depressive disorder and direclidine for schizophrenia and bipolar mania, as well as next-generation VMAT2 inhibitors and CRF-based therapies for metabolic diseases like obesity.
Another major theme in Neurocrine Biosciences news is financial and corporate reporting. The company announces quarterly net product sales for INGREZZA and CRENESSITY, provides guidance ranges for research and development and selling, general and administrative expenses, and discusses its R&D strategy at events such as its annual R&D Day and healthcare investor conferences. Management presentations at large industry meetings, including the J.P. Morgan Healthcare Conference and other investor conferences, are also highlighted in press releases.
This NBIX news page aggregates these updates so readers can quickly review earnings announcements, clinical milestones, R&D strategy briefings, investor conference appearances and key scientific publications related to Neurocrine Biosciences. For anyone tracking developments in tardive dyskinesia, Huntington’s disease chorea, classic congenital adrenal hyperplasia, neuropsychiatric disorders or emerging CRF-based metabolic therapies, the news stream provides a concise view of the company’s ongoing activities and disclosures.
Neurocrine Biosciences (Nasdaq: NBIX) presented the first expert consensus recommendations for screening, diagnosis and treatment of tardive dyskinesia (TD) in long-term care on March 26, 2026. The multidisciplinary Delphi panel endorses routine AIMS screening, quarterly checks for residents on dopamine blockers, and use of VMAT2 inhibitors with tailored selection factors.
A post-hoc KINECT-PRO analysis in adults 65+ shows clinically meaningful patient-reported improvements with once-daily INGREZZA (valbenazine) at Week 24, and the company highlights formulation and dosing features relevant for long-term care residents.
Neurocrine Biosciences (Nasdaq: NBIX) on March 17, 2026 promoted Andrew Ratz, Ph.D., to Chief Technical Operations Officer. Dr. Ratz will lead global technical development, manufacturing and supply chain as the company expands beyond small molecules into biologics and device-based therapies.
Dr. Ratz joined Neurocrine in January 2025 as Senior Vice President of Drug Development, Delivery and Device and brings nearly 30 years of prior executive experience at Eli Lilly. He contributed to the development and registration of more than 25 medicines and holds a B.S. in Chemistry from Indiana University and a Ph.D. in Chemistry from Harvard University.
Neurocrine Biosciences (Nasdaq: NBIX) will present at the Stifel 2026 Virtual CNS Forum on March 17, 2026 at 4:30 PM ET. The management team will participate and deliver prepared remarks.
A live webcast will be available on the company website under Investors and a replay will be posted about one hour after the event and archived for approximately one month.
BetterInvesting Magazine named Equifax (NYSE: EFX) and Neurocrine Bio (NASDAQ: NBIX) as "Stock to Study" for the May 2026 issue, urging investor research and education rather than buy recommendations.
The Editorial Advisory and Securities Review Committee highlighted fundamental data availability and called both companies worthy of further study for investors using the Stock Selection Guide.
Neurocrine Biosciences (Nasdaq: NBIX) said members of management will present at investor conferences in March 2026, including TD Cowen on March 3 at 11:50 AM ET and Leerink Global on March 9 at 8:40 AM ET.
Live webcasts will stream on the company's investor website with replays posted about one hour after each event and archived for roughly one month.
Neurocrine Biosciences (NASDAQ: NBIX) reported Q4 2025 net product sales of $798.3M and full‑year 2025 net product sales of $2.83B, up 29% and 22% YoY. INGREZZA full‑year 2026 net product sales guidance is $2.7–$2.8B. GAAP Q4 net income was $153.7M (EPS $1.48); GAAP FY net income was $478.6M (EPS $4.67). Cash and marketable securities totaled approximately $2.54B at Dec 31, 2025. Company cited increased R&D and SG&A investments to support Phase 3 programs and CRENESSITY launch activities.
Neurocrine Biosciences (Nasdaq: NBIX) initiated a Phase 2 randomized, double-blind, placebo-controlled study of investigational NBI-1065890 in adults with tardive dyskinesia (TD) on Jan 26, 2026. NBI-1065890 is described as a next-generation, selective VMAT2 inhibitor designed for a potentially differentiated, longer-acting profile.
The study will enroll approximately 100 adults and will assess efficacy, safety, and tolerability versus placebo. The primary efficacy endpoint is change from baseline in the AIMS dyskinesia total score (Items 1–7) at Week 8. Neurocrine notes prior FDA approvals for valbenazine in 2017 (tardive dyskinesia) and 2023 (Huntington’s chorea).
Neurocrine Biosciences (Nasdaq: NBIX) will host its fourth quarter and year-end 2025 financial results conference call and webcast on February 11, 2026. The press release will be issued at 1:00 p.m. PT / 4:00 p.m. ET, followed by the conference call at 1:30 p.m. PT / 4:30 p.m. ET. Domestic dial-in: 800-579-2543; international dial-in: 785-424-1789; conference ID: NBIX. The webcast will be available at neurocrine.com under Investors, with a replay posted about one hour after the event and archived for ~one month.
Neurocrine focuses on treatments for neurological, psychiatric, endocrine and immunological disorders and maintains a mid-to-late phase clinical pipeline.
Neurocrine Biosciences (NASDAQ: NBIX) presented head-to-head PET imaging data comparing VMAT2 target occupancy for INGREZZA (valbenazine) versus AUSTEDO XR (deutetrabenazine) at therapeutic doses on January 15, 2026. The primary analysis reported a least-squares mean VMAT2 occupancy of ~76.5% for INGREZZA versus ~38.3% for AUSTEDO XR after single doses. Estimated steady-state occupancies were 83%/92% for INGREZZA (40/80 mg) and 54%/70% for AUSTEDO XR (24/48 mg). Both drugs were generally well tolerated; findings were presented at ACNP Jan 12–15, 2026.
Neurocrine Biosciences (Nasdaq: NBIX) will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 9:45 a.m. Pacific Time in San Francisco. Kyle Gano, Chief Executive Officer, will deliver the presentation.
The live webcast can be accessed via the company's Investors website at neurocrine.com. A replay will be posted approximately one hour after the event and archived for about one month.
Neurocrine is a neuroscience-focused biopharmaceutical company with FDA-approved treatments across tardive dyskinesia, Huntington's chorea, classic congenital adrenal hyperplasia, endometriosis and uterine fibroids (collaboration with AbbVie), and a mid- to late-stage clinical pipeline.